Jeffrey A. Bailey

Director

Since 2020, Jeffrey A. Bailey has served as Chairman of the Board at Tekla Capital Management, a registered investment adviser, based in Boston, with four, multi-billion dollar, closed-end funds that predominately invest in the securities of public and private healthcare companies. He has also been Chairman of the Board of Aileron Therapeutics since 2017. 

Mr. Bailey has significant pharmaceutical and biotech leadership experience, with expertise in supply chain, commercial, finance, business development, and product development. He has deep experience managing shareholder expectations and company objectives to achieve a successful outcome. Mr. Bailey has held multiple President, Chief Executive Officer, and leadership roles at biotech and pharmaceutical companies where he oversaw improvements in strategic operations and led the organizations through successful acquisitions, including BioDelivery Sciences (2020-2022), Illuminoss (2018-2020), Neurovance (2015-2017), Lantheus Medical Imaging (2013-2015), and Fougera Pharmaceuticals (2011-2012).

From 2010 to 2011, Mr. Bailey served as Chief Commercial Officer at King Pharmaceuticals, where he led more than 750 employees delivering more than $1.5 billion in annual sales. From 2008 to 2010, Mr. Bailey was President and General Manager at Novartis, where he led a 1000-member primary care and specialty pharma team delivering more than $825 million in sales. 

Mr. Bailey began his career in 1984 at the Johnson & Johnson Family of Companies where he earned successive leadership roles over the course of 20 years. He holds a degree in Business Administration from Rutgers University in New Brunswick, NJ.